Contact
Please use this form to send email to PR contact of this press release:
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
TO:
Please use this form to send email to PR contact of this press release:
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
TO: